ANPC.F Stock Overview
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ANGLE plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.23 |
| 52 Week High | UK£0.35 |
| 52 Week Low | UK£0.13 |
| Beta | 0.12 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -64.00% |
| Change since IPO | -85.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANPC.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 1.2% |
| 1Y | n/a | -0.7% | 24.7% |
Return vs Industry: Insufficient data to determine how ANPC.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how ANPC.F performed against the US Market.
Price Volatility
| ANPC.F volatility | |
|---|---|
| ANPC.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANPC.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ANPC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 173 | Andrew David Newland | angleplc.com |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer.
ANGLE plc Fundamentals Summary
| ANPC.F fundamental statistics | |
|---|---|
| Market cap | US$38.67m |
| Earnings (TTM) | -US$27.56m |
| Revenue (TTM) | US$2.25m |
17.2x
P/S Ratio-1.4x
P/E RatioIs ANPC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANPC.F income statement (TTM) | |
|---|---|
| Revenue | UK£1.82m |
| Cost of Revenue | UK£1.50m |
| Gross Profit | UK£319.00k |
| Other Expenses | UK£22.60m |
| Earnings | -UK£22.28m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | 17.55% |
| Net Profit Margin | -1,225.41% |
| Debt/Equity Ratio | 0% |
How did ANPC.F perform over the long term?
See historical performance and comparison